A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to evaluate the
safety, tolerability and recommended Phase 2 dose of MM-121 in combination with standard
therapy.

Phase 2: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to estimate the
progression-free survival of the MM-121 + standard therapy.

Inclusion Criteria:

- Patients with locally advanced or metastatic non-small cell lung cancer.

- Patients must be >/= 18 years of age.

- Patients must have adequate Performance Status (PS) as measured by ECOG and adequate
end organ function.

Exclusion Criteria:

- Patients with a recent history (within 5 years) of another malignancy.

- Patients who are pregnant or nursing.

- Patients with clinically significant heart failure.

- Patients with clinically significant eye or gastrointestinal abnormalities.